Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain. (Q45992613)

18 December 2017

title

Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain. (English)

1 reference

18 December 2017

author name string

G Villa

1

1 reference

18 December 2017

L J Hernández-Pastor

2

1 reference

18 December 2017

M Guix

3

1 reference

18 December 2017

J Lavernia

4

1 reference

18 December 2017

M Cuesta

5

1 reference

18 December 2017

publication date

1 July 2014

1 reference

18 December 2017

Clinical and Translational Oncology

published in

1 reference

18 December 2017

volume

17

1 reference

18 December 2017

issue

1

1 reference

18 December 2017

page(s)

24-33

1 reference

18 December 2017

https://scigraph.springernature.com/pub.10.1007/s12094-014-1191-9

exact match

0 references

cites work

Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Rare cancers are not so rare: the rare cancer burden in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Quality of life trajectory in patients with advanced cancer during the last year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Elicitation of health state utilities in soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Elicitation of health state utilities in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Health state utilities for non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Indirect comparisons of competing interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1191-9

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic ana

21 January 2018

1 reference

12 December 2020

Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group

1 reference

12 December 2020

1 reference

12 December 2020

Spanish recommendations on economic evaluation of health technologies

1 reference

12 December 2020

Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration

1 reference

12 December 2020

Cost-utility and expected value of perfect information related to trabectedin in the treatment of metastatic soft-tissue sarcoma: the publicly funded comments explored

1 reference

12 December 2020

The relationship between progression-free and post-progression survival in treating four types of metastatic cancer

1 reference

12 December 2020

[Soft tissue sarcomas: clinical practice guidelines]

1 reference

12 December 2020

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

12 December 2020

10.1007/S12094-014-1191-9

Identifiers

DOI

1 reference

18 December 2017

Dimensions Publication ID

1052083778

0 references

1 reference

18 December 2017